Please type a plus sign (+) inside this box →
---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0851-0031

nd	er the Paperwork Reduction Act of 1995, no	persons are required to re	Patent and Trade spend to a collection of informa	mark Office: U.S. DEPARTMENT OF COMME tion unless it contains a valid OMB control nur	ERCE mber.
1	Substitute for form 1449A/PTO	MAR 0 8 2004	Complete if Known		
		12	Application Number	10/760,515	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known					
Application Number 10/760,515					
Filing Date	01-20-2004				
First Named Inventor	Ronald C. Bernotas, et al				
Group Art Unit					
Examiner Name					
Attorney Docket Number	USHMR2037 US DIV 1				

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.1	U.S. Paten Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
CC		4,908,369		SCHECHTER, ET AL	03-13-1990			
		4,912,117		CARR, ET AL	03-27-1990			
		4,783,471		CARR, ET AL	11-08-1988			
		5,134,149		CARR, ET AL	07-28-1992			
		5,561,144		CARR, ET AL	10-01-1996			
		5,700,813		CARR, ET AL	12-23-1997			
		5,874,445		CARR, ET AL	02-23-1999			
		5,021,428		CARR, ET AL	06-04-1991			
		5,106,855		MCLEES BYRON D.	04-21-1992			
		5,169,096		CARR, ET AL	12-08-1992			
		5,478,846		CARR, ET AL	12-26-1995			
		5,618,824		SCHMIDT, ET AL	04-08-1997			
		5,700,812		CARR, ET AL	12-23-1997	•		
ПП		5,721,249		CARR, ET AL	02-24-1998			
CC		4,877,798		SORENSEN STEPHEN M.	10-31-1989			
						_		
		I						

FOREIGN PATENT DOCUMENTS									
Examiner	Cite		Foreign Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т	
Initials	No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	76	
					, 3				
								L	
		<b>                                     </b>	2-				····	Ļ	
		<del>  </del>						╀	
		<del></del>		<del>-   -  </del> -		1		╁	
		<del>                                     </del>			<u></u>			t	
								T	
								Т	

Examiner Signature	/Celia Chang/	Date 09/14/2006 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a pl	lus sign (+) inside	this box 🛶
------------------	---------------------	------------

2

Sheet

of

MAR 0 8 2004 8

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number.

USHMR2037 US DIV 1

		ı	
•	_	1	_

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Under the Paperwork Reduction Act of 1995, no persons a boquired to respond the collection of information unless it contains a valid OMB control number

Complete if Known

Application Number 10/760,515

Filing Date 01-20-2004

First Named Inventor Ronald C. Bernotas, et al

Group Art Unit

Examiner Name


Attorney Docket Number

xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
cc I		A. A. SINKULA et al., Rationale for Design of Biologically Reversible Drug Derivatives; Prodrugs, Journal Pharmaceutical Sciences (1975, pp.181-210, Volume 64, Issue 2	
		BARRY M. TROST et al., Regioselectivity in Lithiation of T-Butyldimethylsiloxy-3, 5-Dimethoxybenzene., Tetrahedron Letters (1985, pp. 123-126, Volume 26-2)	
		C. A. MATHIS et al., Synthesis and Preliminary in Vivo Evaluation of [11C]MDL 100907: A Potent and Selective Radioligand for the 5-HT2A Receptor System, Med Chem Res (1996, pp. 1-10 Volume 6)	Ī
		CAMILLA LUNDKVIST et al., Improved Syntheses of the PET Radioligands, [11C] FLB 457, [11C]MDL 100907 and [11C] B-CIT-FE, by the use of [11C]Methyl Triflate, Journal of Labelled Compounds and Radiopharmaceuticals (1998, pp.545-556)	
		CHARLES O. WILSON et al., Central Nervous System Depressants, J. B. Lippincott Company Textbook of Organic Medicinal and Pharmaceutical Chemistry (1977, pp.348-349, 7th Edition)	
		DENNIS O. SCOTT et al., Investigation of the CNS Penetration of a Potent 5-HT2a Receptor Antagonist (MDL 100,907) and an active Metabolite (MDL 105,725) Using in Vivo Microdialysis Sampling in the Rat, Journal of Pharmaceutical and Biomedical Analysis (1998, pp. 17-25, Volume 17)	
		JOHN J. LANDI JR. et al., Regioselective Preparation of 4-Formyl-3,5-Dimethoxyphenol, an Intermediate in the Synthesis of the Pal Solid-Phase Peptide Synthesis Handle, Synthetic Communications, (1991, pp. 167-171, Volume 21-2)	
		PAUL L. MUNSON et al., Principles of Pharmacology Basic Concepts & Clinical Applications, Chapman & Hall (1995, pp.52-58)	
		SABINE WALLBAUM et al., Asymmetric Syntheses with Chiral Oxazaborolidines, Tetrahedron: (1992, pp.1475-1504, Volume3-12)	
		TIMOTHY G. HEATH et al., Quantification of a Potent 5-HT2a Antagonist and an Active Metabolite in Rat Plasma and Brain Microdialysate by Liquid Chromatography-Tandem Mass Spectrometry, Journal American Society for Mass Spectrometry (1997, pp. 371-379, Volume 8)	
<u> </u>		YIYUN HUANG et al., An Efficient Synthesis of the Precursors of [11C]MDL 100907 Labeled in Two Specific Positions, Journal of Labelled Compounds and Radiopharmaceuticals (1999, pp.949-957, Volume 42)	

Examiner	/Celia Chang/	Date	/Celia Chang/
Signature		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.





Please type a plus sign (+) Inside this box ->

MAR 0 8 2004

PTO/SB/08B (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

to a collection of information unless it contains a valid OMB control number.

+

Under the Paperwork Reduction Act of 1995, no persons are required to resp

A MADEUS Complete if Known Substitute for form 1449B/PTO **Application Number** 10/760,515 INFORMATION DISCLOSURE 01-20-2004 **Filing Date** STATEMENT BY APPLICANT Ronald C. Bernotas, et al **First Named Inventor** Group Art Unit (use as many sheets as necessary) **Examiner Name** Sheet of **Attorney Docket Number USHMR2037 US DIV 1** 3 3

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>					
cc		DOUDET DORIS J. ET Al, Distribution and Kinetics of 3-O-Methyl-6-[18F]Fluoro-L-DOPA in the rhesus monkey Brain, J. CEREB. (1991, pp. 726-734, Volume 11-5)						
cc		ROSE FREDERICK A. ET AL., Metabolism of 5-Hydroxytryptamine o-sulfate- [35S] in the rat; Journal Biochem. (1971, pp. 601-603, Volume 122-4)						
0.0		•						
		·						

Examir	45.31.61	,	Date	00/14/0006
CABITIE	Celia Char	ig/	Date	09/14/2006
Signati	e		Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.